CPhi Korea Opens As South Korea Emerges As Global Leader In Biosimilar Trials

Government’s R&D strategy and “Pharma 2020 Vision” to see country as drug development leader

Amsterdam, 27 July 2015: CPhI Korea (#CPhIKorea), organised by UBM EMEA, will return to the COEX in Seoul, South Korea – 7 to 9 September 2015 – following a successful inaugural event last year. Co-organised by the Korean Pharmaceutical Traders Association, the event will be co-located with ICSE, P-MEC and BioPh. Together, these four-events-in-one, provide an unrivalled meeting point for global suppliers of raw materials, machinery, contract services and bio-solutions to interact with domestic and international visitors and deliver pharmaceutical products across Asia and the wider globe.

The pharmaceutical economy in South Korea is expected to reach a value of over $24 billion by 2020 and following the country’s “Pharma 2020 Vision”, the Government has committed $8.9 billion to drug development over the next five years. Investment in biotechnology is increasing, with annual double-digit growth expected in this sector over the coming years. Most significantly, South Korea has the largest number of biosimilar clinical trials and targets in its pipeline, making it the global leader for development within this class.

Last year, South Korea reached a milestone in joining The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), which allowed domestic companies in the South Korean pharma industry to advance into foreign markets. CPhI Korea aims to provide an even bigger platform this year for such international collaboration, growing in tandem with the wider economy.

The South Korean market is already the fifteenth largest pharmaceutical market in the world and CPhI Korea has expanded to a three-day event, with an exhibition space that is three times larger in 2015. Over 3000 attendees and 150 exhibitors from an estimated 50 countries are set to gather in South Korea for the event’s second edition.

Chris Kilbee, Group Director at UBM EMEA commented: “We are delighted to return to South Korea for a second year, with an expanded exhibition and content portfolio. After such a successful opening event last year, we are very excited to be delivering a more market-focused exhibition at such a key time for this regional hot-bed of pharma innovation.

Over the next few years, strong growth is forecast for South Korea, thanks to the Government’s “Pharma 2020” plan and pushing ahead with increased R&D investment – it really is a dynamic time to enter this market. Moreover, CPhI Korea plays an essential role in gathering pharma companies and executives from across Asia and the globe, and provides an unrivalled central hub for creating business opportunities and partnerships.”

Highlights of CPhI Korea 2015:

Co-location with ICSE, P-MEC and BioPh, providing services and opportunities across the whole supply chain The 1:1 Business Matchmaking Programme enables exhibitors to target specific companies for forwarding business opportunities through 1:1 meetings organised prior to arrival CPhI Korea Conference Programme that is set to explore the world’s pharma trends

Ministry of Food and Drug Safety, Korea Drug Research Association and Korea Biomedicine Industry Association are all sponsors of CPhI Korea 2015.

-ENDS-

Notes to editors

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, Southeast Asia, Istanbul, Russia and South America and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.

For more information visit: www.cphi.com

The UBM EMEA annual schedule of Pharmaceutical events includes; CPhI Korea (7-9 September, 2015 at the COEX Hall D- Seoul, South Korea); CPhI, ICSE, P-MEC and InnoPack Worldwide (13-15 October 2015, IFEMA- Feria de Madrid, Spain); CPhI, P-MEC, ICSE and BioPh India (1-3 December, 2015 at the Bombay Convention and Exhibition Centre, Mumbai, India); CPhI, P-MEC and Innopack South East Asia (06-08 April, 2016 at the Jakarta International Expo- Jakarta, Indonesia); CPhI, ICSE, P-MEC, BioPh and InnoPack Japan (20-22 April, 2016 at the Big Sight Exhibition Centre- Tokyo); CPhI Istanbul (1-3 June, 2016 at the ICC Istanbul Congress Center, Istanbul, Turkey); CPhI China and P-MEC (21-23 June, 2016 at SNIEC, Shanghai, China).

About UBM EMEA

UBM EMEA connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.

For media enquiries, please contact:

Alex Heeley or Tristan Jervis
De Facto Communications
T: +44 207 203 6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC